Unum Therapeutics Inc (NASDAQ:UMRX) – Wedbush issued their Q1 2020 earnings per share (EPS) estimates for shares of Unum Therapeutics in a report released on Tuesday, November 5th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.20) per share for the quarter. Wedbush has a “Outperform” rating and a $13.00 price target on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.23) EPS, Q4 2020 earnings at ($0.20) EPS, FY2022 earnings at ($1.44) EPS and FY2023 earnings at ($0.96) EPS.
Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 75.60%. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million.
UMRX has been the subject of a number of other research reports. Cowen reissued a “hold” rating on shares of Unum Therapeutics in a research note on Monday, August 12th. ValuEngine raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered shares of Unum Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Unum Therapeutics in a research note on Tuesday, August 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Unum Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $9.63.
Shares of NASDAQ:UMRX traded up $0.01 during trading on Friday, reaching $1.26. 48,800 shares of the company traded hands, compared to its average volume of 115,060. The firm has a fifty day simple moving average of $1.48 and a 200 day simple moving average of $2.30. The firm has a market cap of $39.55 million, a P/E ratio of -0.91 and a beta of 1.25. Unum Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.41. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.13.
Several hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its stake in shares of Unum Therapeutics by 134.8% in the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after purchasing an additional 18,717 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Unum Therapeutics in the 3rd quarter valued at $31,000. Susquehanna International Group LLP acquired a new stake in shares of Unum Therapeutics in the 2nd quarter valued at $62,000. Wedbush Securities Inc. acquired a new stake in shares of Unum Therapeutics in the 3rd quarter valued at $48,000. Finally, Jane Street Group LLC acquired a new stake in shares of Unum Therapeutics in the 2nd quarter valued at $132,000. 42.07% of the stock is owned by institutional investors and hedge funds.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Further Reading: What is an economic bubble?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.